UNSPSC 51312604: Etintidine

This classification denotes a histamine-2 receptor antagonist with the molecular formula C12H16N6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, A60Z457SSF chemically known as guanidine, n''-cyano-n-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)-n'-2-propynyl- but generally known as etintidine, which bears US NIH Compound Identifier 150172. European Medicines Agency schedules Etintidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07305MIG.

UNSPSC 51312604 Etintidine is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The three opportunities posted against this code—a county naloxone and drug deactivation systems purchase, a state health agency RFI on direct-to-manufacturer pharmacy programs, and a multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products—involve naloxone, pharmacy benefit management, and generic drug sourcing respectively, but none concern etintidine specifically. The mismatch suggests either a data-entry error in the tagging or that etintidine procurement activity is not currently reflected in state and local solicitations.

The opportunities that do carry this code show activity across county health departments, state health and human services agencies, and multistate cooperative purchasing vehicles. Seminole County, Florida issued an IFB (solicitation IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas Health and Human Services Commission posted an RFI in April 2026 to gather vendor capability data on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued an RFP in January 2026 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon. Geographic activity spans Florida, Texas, and the upper Midwest. The code shows little relevant recent activity in its nominal scope; business developers should verify coding accuracy with issuing bodies before pursuing opportunities listed under it.